To determine the effect of the pharmacological inhibition of PKC in vivo, NSG-SGM3 mice were transplanted with CML CD34+ cells, and 10 days post-transplant, were treated with either the PKC inhibitor Ro-31-8200 or imatinib or both imatinib and Ro-31-8200, or treated with PBS (Control) (Fig. 6k). Here, PRRT2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.